Chordia Therapeutics Company Description

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan.

It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099.

The company was incorporated in 2017 and is based in Fujisawa, Japan.

Chordia Therapeutics Inc.

Country	Japan
Founded	2017
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	23
CEO	Hiroshi Miyake

Contact Details

Address: 26-1, Muraoka-Higashi 2-chome Fujisawa, 251-0012 Japan
Website	chordiatherapeutics.com

Stock Details

Ticker Symbol	190A
Exchange	Tokyo Stock Exchange
Fiscal Year	September - August
Reporting Currency	JPY
ISIN Number	JP3283730004
SIC Code	2836

Key Executives

Name	Position
Hiroshi Miyake	Chief Executive Officer